Stüve-Wiedemann syndrome (STWS; OMIM #610559) is a rare disease that results in dysfunction of the autonomic nervous system, which controls involuntary processes such as breathing rate and body temperature. In infants, this can result in respiratory distress, feeding and swallowing difficulties, and hyperthermic episodes. Individuals may sweat excessively when body temperature is not elevated. Additionally, individuals have reduced ability to feel pain and may lose reflexes such as the corneal reflex that normally causes one to blink, and the patellar reflex resulting in the knee-jerk. STWS usually results in infant mortality, yet some STWS patients survive into early adulthood. STWS is caused by a mutation in the leukemia inhibitory factor receptor (LIFR) gene, which is inherited in an autosomal-recessive pattern. Most LIFR mutations resulting in STWS cause instability of the mRNA due to frameshift mutations leading to premature stop codons, which prevent the formation of LIFR protein. STWS is managed on a symptomatic basis as no treatment is currently available.
Introduction
Stüve-Wiedemann syndrome (STWS) was first described in 1971 in two sisters with congenital bowing of the tibia and femur. While both patients experienced respiratory distress and died within a few days, one also suffered from hyperthermia 1, 2 . Although the prognosis of STWS remains poor today, recent reports show that some STWS patients survive into adulthood 3, 4 . STWS patients are phenotypically identical to Schwartz-Jampel syndrome type 2 (SJS2) patients 5, 6 , and both SJS2 and STWS have been linked to a mutation of the leukemia inhibitory factor receptor (LIFR) gene on chromosome 5p13.1, and SJS2 and STWS are now considered the same syndrome 7 . STWS is found across multiple ethnic groups in multiple regions of the world including North America, Europe, and the Middle East 7,8-12 .
The skeletal features of STWS place it within the bent-bone dysplasias 13 , characterized by bowing of the long bones with cortical thickening and rarefaction, wide and blurred margins of the metaphyses, contracture and limited mobility of elbows and knees, osteopenia, flared iliac wings, hypoplasia of the lower ilia, and an abnormal trabecular shape 1, 7, 9, 14 . Progressive bowing of the long bones, severe spinal deformities, osteoporosis and spontaneous fractures occur. Joints may be prominent with restricted mobility. While skeletal features are important, skeletal symptoms will not be the focus of this review, and we will restrict our discussion to nervous system symptoms.
. Temperature instability is accompanied by excessive and paradoxical sweating. Other signs of dysautonomia persist, such as a smooth tongue, absent corneal and patellar reflexes, and reduced pain sensation. Physical growth and motor development is delayed, but intelligence is normal [7] [8] [9] . The smooth tongue phenotype seen in STWS is due to a lack of fungiform papillae, normally found on the upper surface of the tongue. The inner structural connective tissue of fungiform papillae is highly innervated and provides the ability to distinguish taste. Taste bud development and maintenance is strictly dependent on the innervation during early postnatal development, and fungiform papillae do not develop when innervation is obstructed 18 . Additionally, fungiform papillae do not develop in the absence of a functional LIFR or signaling by LIF and CNTF 19 . Lack of fungiform papillae is both a structural and a neurological pathology of STWS. A smooth tongue due to their absence is a key indicator of the role LIFR plays in normal neuronal development of taste buds, and an important symptom that STWS patients encounter.
Genetic etiology
The mutated LIFR gene is inherited in an autosomal recessive pattern. The mutations reported to date have been missense or nonsense mutations, with the majority of mutations occurring within the exons encoding the extracellular domain 7 . The LIFR gene has 20 exons, 19 of which encode amino acids of this transmembrane protein which is 1,097 amino acids long 7, 20, 21 .
Mouse genetic models have informed us of phenotypes resembling STWS. LIFR null mice display a strikingly similar phenotype consistent with STWS patients 22 . The number of motor neurons in the facial nucleus, lumbar spinal cord, and nucleus ambiguous are severely reduced in mice that do not express LIFR 23 . Importantly for STWS, the nucleus ambiguus innervates the esophagus, pharynx, larynx, and coordinates swallowing and is responsible for initiating the respiratory rhythm.
Genetic Variability
Although not all STWS patients have an identified LIFR mutation 9,17 , other genes responsible for the STWS phenotype have not been identified. Additional genes within the chromosomal region 5p13.1 from locus D5S194 to D5S1457 mapped by Dagoneau et al. included FLJ39155 (EGFLAM or Pikachurin, a proteoglycan), disabled-2 (DAB2), complement 9 (C9), Fyn-binding protein (FYB), and oncostatin M receptor (OSMR) 7 . While these genes may play a role as disease modifiers or may be potential candidates for those cases of STWS that are not linked to a mutation in LIFR, to date, limited information exists to support the likelihood of the involvement of these genes in skeletal, respiratory or neurological symptoms associated with the syndrome. Respiratory function has been associated with DAB-2. DAB-2 is a clathrin-associated sorting protein (CLASP) that contributes to clathrin recruitment, vesicle formation, and cargo selection. In the lungs, cystic fibrosis transmembrane conductance regulator, a cAMP-activated chloride channel expressed in the apical plasma membrane of human airway epithelial cells, is endocytosed in a DAB-2-dependent manner 24 . DAB-2 also plays a role in bone morphogenetic protein signaling 25 and nerve cell differentiation 26 . Additionally, a neurologic function has been described for FYB through an association with hereditary motor-sensory neuropathy 27 . OSMR, like LIFR, is able to bind to glycoprotein (gp)130 to form heterodimers within the plasma membrane. OSMR has also been implicated in the respiratory system 28 , and the nervous system 29 , as well as metabolic symptoms such as mature-onset obesity, severe hepatic steatosis, and insulin resistance 30 .
OSMR plays a key role in bone homeostasis as demonstrated by the OSMR( -/-) mouse, which exhibits an osteopetrotic phenotype due to an effect on osteoclast differentiation 31, 32 . The OSMR ( -/-) mouse however, does not display the autonomic manifestations seen in STWS patients, suggesting that loss of OSMR by itself would not result in STWS. Therefore, the presence of OSMR within the candidate region is likely due to gene duplication and its presence within the candidate region is probably coincidence.
Proteins that play an essential role in the LIFR signaling pathway as ligands or as competing receptor, such as the cytokine receptor-like factor 1 (CRLF1), cardiotrophin-like cytokine factor 1 (CLCF1), neuropoietin (NP), and ciliary neurotrophic factor (CNTF) may play a role in the neuronal symptoms of STWS 9 and are discussed in more detail.
The lifr protein and signaling The LIFR Protein
The LIFR protein (glycoprotein-190; gp 190) is composed of a signal peptide followed by three main domains. The extracellular domain (45-833aa) includes two cytokine receptor homology domains (CRH1 and CRH 2), one Iglike domain (Ig), and one type III fibronectin domain with three modules (FNIII). The transmembrane domain (TM; 834-858aa) is located between the extracellular domain and the cytoplasmic domain (CD; 859-1097aa) ( Figure 1 ).
The LIFR Signaling Pathway
LIFR binds with low affinity to several IL-6 cytokine family members, including leukemia inhibitory factor (LIF), oncostatin-M (OSM), cardiotrophin-1 (CT-1, also abbreviated as CTF-1), ciliary neurotrophic factor (CNTF), neuropoietin (NP also abbreviated CTF2 in mouse, and CTF2P in human), and cardiotrophin-like cytokine factor 1 (CLCF-1, also abbreviated as CLC) [33] [34] [35] [36] (Figure 2 ). Both LIF and OSM bind to the LIFR. LIF binds to LIFRβ, which then recruits gp130 for higher affinity and cell signaling 21 . In contrast, OSM binds gp130 with low affinity but has little to no biological activity unless a second receptor chain is recruited, either the LIFRβ or the more highly specific OSMRβ [37] [38] [39] [40] . CT-1 binds to gp130 and LIFR 41 , while CNTF first binds to ciliary neurotrophic factor receptor (CNTFRα) before recruiting LIFR 42 . NP signals through a receptor complex comprising CNTFRα, gp130, and LIFR 43 . Cardiotrophin-like cytokine factor 1 (CLCF-1) forms a heterodimer with either cytokine receptor-like factor 1 (CRLF1) or soluble ciliary neurotrophic factor receptor (sCNTFR) and competes for this same receptor complex 9, [44] [45] [46] . CNTF, LIF, and NP may be responsible for neuronal development and survival, as CTNF possesses neurotrophic activity and can enhance precursor self-renewal and expansion of neuronal stem cells 47, 48 . CTNF and LIF may play a role in motor neuron innervation [49] [50] [51] and NP can sustain in vitro survival of embryonic motor neurons and can increase the proliferation of neural precursors 52 (Table 1 ).
Lifr ligands linked to neuronal development

Leukemia Inhibitory Factor
LIF is a pleiotropic cytokine, secreted by a variety of cell types, including epithelial and stromal cells 53 , osteoblasts 54,55 , bone marrow stromal cells, fibroblasts, astrocytes, heart myoblasts, T lymphocytes, monocytes, and thymic epithelial cells among others 56 .
LIF acts as a neurotrophic factor 57 and may play a role in motor neuron innervation [49] [50] [51] . LIF is known to stimulate cholinergic differentiation in sympathetic neurons, inducing choline acetyltransferase gene expression, which in turn promotes the survival of cholinergic neurons 58 . Similarly, LIF is important for the cholinergic transdifferentiation of cardiac sympathetic neurons. Hence, it is likely that a lack of LIF downstream signaling leads to the cardiovascular phenotype seen in STWS [59] [60] [61] . LIF also has neuromodulary roles in the respiratory airways 62 . LIF enhances the differentiation and survival of motor neurons.
Oncostatin-M (OSM)
OSM shares similarities with LIF, as both are able to induce the differentiation of myeloid leukemia cells to macrophage-like cells in mice 63 . LIF and OSM are located near each other on chromosome 22, and their arrangements suggest that LIF and OSM may be the result of a gene duplication event of an ancestral gene 64 .
The reduction in motor neurons seen in STWS is due in part to the inability of OSM to signal through the mutated LIFR 23 . OSM is likely to be one of the LIFR ligands responsible for the respiratory distress and dysphagia seen in STWS.
Cardiotrophin-1 (CT-1)
CT-1 plays an important role in the cholinergic transdifferentiation of cardiac sympathetic neurons in rodents 59, 65 . Specifically, CT-1 loss reduced the number of preganglionic sympathetic neurons, which are important for inducing heart rate, ventricular pressure, and contractility 66 . CT-1 is also known to induce cardiac myocyte hypertrophy and vascular smooth muscle cell proliferation in vitro 60 . Therefore, the lack of CT-1 signaling in STWS may play a role in the cardiovascular phenotype 67 and in motor neuron survival 68 . A role for CT-1 in airway smooth muscle cells has been identified 69, 70 , and therefore, an absence of CT-1 signaling in STWS may contribute to the respiratory phenotype of STWS. Similarly, CT-1 is important for the cholinergic transdifferentiation of cardiac sympathetic neurons. Hence, it is likely that a lack of CT-1 downstream signaling leads to the cardiovascular phenotype seen in STWS [59] [60] [61] . The reduction in motor neurons seen in STWS is due in part to the inability of CT-1 to signal through the mutated LIFR 23 . CT-1 is likely to be responsible for the respiratory distress and dysphagia seen in STWS.
Ciliary Neurotrophic Factor (CNTF)
STWS includes autonomic nerve dysfunction 3 , and ciliary neurotrophic factor receptor (CNTFR) gene has also been linked to autonomic nervous system dysfunction 71, 72 . CNTF is expressed in the developing nervous system, particularly in the motor neurons, and it plays a role in motor neuron survival 23 . CNTF are known to stimulate cholinergic differentiation in sympathetic neurons, inducing choline acetyltransferase gene expression, which in turn promotes the survival of cholinergic neurons 58 . CNTF enhances the differentiation and survival of motor neurons. Mice deficient in CNTF do not show a decrease in motor neurons.
Neuropoietin (NP; CTF2; CTF2P)
Neuropoietin is encoded by the CTF2 gene in the mouse and CTF2P in human. The approved name is cardiotrophin 2, pseudogene in humans. It was described in 2004 by Derouet and colleagues 52 Table 1 : LIFR ligand and associated symptoms Each of the cytokines signal through the leukemia inhibitory factor receptor (LIFR). In STWS, the LIFR gene is mutated, and due to the mutation, cytokine signaling is blocked, and the corresponding manifestations of STWS occur. Only symptoms for which the mechanism has been explored are listed. Those followed by a question mark are still under considerable speculation. LIF: leukemia inhibitory factor; CNTF: ciliary neurotrophic factor; OSM: oncostatin-M; CT-1: cardiotrophin-1; CLCF1: cardiotrophin-like cytokine factor-1; CRLF1: cytokine receptor-like factor-1. Neuropoietin is not included in the table.
the cardiotrophin-1 gene. NP or CTF2, is predominantly expressed in mouse neuroepithelia during embryonic life, acts through a receptor complex comprising CNTFRα component, gp 130, and LIF receptor. Like CNTF, it promotes the survival of embryonic motor neurons and could increase the proliferation of neural precursor cells. Interestingly, the human gene has evolved into a pseudogene due to an 8 base pair deletion causing a disruption in the reading frame. This suggests that signaling via CNTF can compensate in the absence of a functional CTF2 in humans. While NP (CTF2) plays key roles in other mammals, it does not play a role in the symptoms of STWS.
NP is highly expressed in embryonic neuroepithelia and in the retina. NP can sustain the in vitro survival of embryonic motor neurons and could increase the proliferation of neural precursors. NP induces neuroepithelial cells to differentiate into astrocytes, and does so in coordination with bone morphogenetic protein 2 (BMP2) 43, 52, 73 .
Cardiotrophin-like Cytokine Factor-1 (CLCF-1)
Crisponi syndrome and cold-induced sweating syndrome share some features with STWS, such as feeding difficulties, trismus, paradoxical sweating (i.e., sweating with low body temperatures 72 ), and hyperthermic episodes 74 . Crisponi syndrome is now considered to be the same disorder as cold-induced sweating syndrome 75 , and cold-induced sweating syndrome is caused by mutations in the CLCF-1 or CRLF-1 genes. CLCF-1 binds with either CRLF-1 (cytokine receptor-like factor-1) or sCNTFR (soluble ciliary neurotrophic factor receptor) and then competes with CNTF (ciliary neurotrophic factor) for the receptor complex composed of CNTFR, LIFR and gp130 43, 45, 76 . Therefore, it is likely that the dysautonomic symptoms seen in STWS are caused by a lack of CLCF-1/ CRLF-1 signaling due to a mutated LIFR gene. Additionally, Clcf-1/Crlf-1 is responsible for cholinergic differentiation of neurons innervating sweat glands 77 .Mice lacking Crlf-1, Cntfr and Clcf-1 are unable to suckle and die shortly after birth 78 . These mice also have a reduced number of motor neurons in the facial nucleus 79 . Therefore, a lack of CLCF-1/CRLF-1 signaling leads to dysphagia and facial muscle contractions observed in STWS.
Future directions
Although most reported cases of STWS are associated with a mutation in the LIFR gene, some diagnosed cases do not have a demonstrable mutation in the LIFR gene. Although it is possible that those patients were misdiagnosed, as STWS shares many traits with other syndromes, it is also very likely that other genes play a role in STWS. Identical frameshift mutations in the LIFR gene in different individuals have also been reported to show differing outcomes or severity.
Even in the cases where LIFR signaling is known to be the root cause of STWS, connections between signaling and symptoms have not been fully elucidated. As many cytokines possess redundant roles, it is likely that there is overlap in function. Additional proteins involved in STWS will likely be discovered as additional research is carried out.
The future holds promise for potential new treatments for STWS. In the case where a single mutation causes STWS, gene editing technologies such as CRISPR/Cas9 may be used to directly modify and correct the STWS associated change in the genome 80 . If successful, correcting the LIFR gene could result in the expression of a normal and functional LIFR protein. Antisense mediated exon skipping may also be a useful strategy in cases where exons encode independently folding domains within the protein or where the remaining domain can still fold stably and correctly and carry out the function of the normal protein 81 . Exon skipping strategies may be especially applicable in cases where a mutation causes a change in reading frame, and skipping of an exon will restore the proper reading frame. Many of the identified disease causing mutations are nonsense mutations, introducing a premature stop codon within the coding regions, resulting in the production of a truncated protein or alternatively, mRNA template degradation. It may be possible to promote read-through of premature stop codons using aminoglycoside antibiotic treatment [82] [83] [84] that influences the fidelity of the stop codon recognition by changing the conformation of the rRNA. 5-(fluorophenyl)-1,2,4-oxadiazolyl-benzoic acid has also been suggested to suppress nonsense mutations by read-through and is being considered for the treatment of cystic fibrosis and may also be applicable for STWS nonsense mutations 85 .
Conclusions
STWS is a rare bent-bone dysplasia with dysautonomic manifestations that is generally caused by the autosomal recessive inheritance of a mutated LIFR gene. The symptoms of STWS are the result of a lack of LIFR signaling, although the exact mechanisms remain unclear for most phenomena. There is currently no treatment available for STWS. Instead, symptoms are managed accordingly. The prognosis remains poor and there are many unanswered questions regarding its pathology. Therefore, further research is needed to provide a better mechanistic understanding as well as to make progress toward novel therapies that take advantage of what we do know about the targeted manipulation of specific signaling pathways.
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